胰腺癌患者自我报告结局评估工具的研究进展

doi:10.3761/j.issn.0254-1769.2020.11.020

摘要/Abstract

摘要：

对胰腺癌患者自我报告结局评估工具进行综述,并分别对胰腺癌患者普适性、特异性自我报告结局评估量表的特性、应用领域等展开阐述,分析现有自我报告结局评估工具存在的问题并提出建议,为胰腺癌患者自我报告结局评估工具的本土化发展以及临床护士选择合适的评估工具,并开展相关研究提供参考。

关键词: 胰腺肿瘤, 患者自我报告结局, 评估工具, 综述, 肿瘤护理

Abstract:

This paper reviewed the patient-reported outcomes and assessment tools for patients with pancreatic cancer and summarized the characteristics and application of generic and specific patient-reported outcome measures. We also proposed and analyzed the existing problems and put forward related suggestions for patient-reported outcome measures, so as to provide references for the localized development of patient-reported outcome measures in patients with pancreatic cancer and for clinical nurses to select appropriate assessment tools and carry out related research.

Key words: Pancreatic Neoplasms, Patient-Reported Outcomes, Assessment Tools, Review, Oncologic Nursing

董丽, 卢芳燕, 吕斐翠, 丁维燕. 胰腺癌患者自我报告结局评估工具的研究进展[J]. 中华护理杂志, 2020, 55(11): 1718-1722.

DONG Li, LU Fangyan, LÜ Feicui, DING Weiyan. Research progress on an assessment tool of patient-reported outcomes for pancreatic cancer patients[J]. Chinese Journal of Nursing, 2020, 55(11): 1718-1722.

参考文献 39

[1]	沈鸣雁, 卢芳燕, 王仁芳, 等. 针对胰腺癌患者的多学科专业化护理实践与成效[J]. 中华护理杂志, 2016,51(5):542-546.
	Shen MY, Lu FY, Wang RF, et al. Effectiveness of nursing care of patients with pancreatic cancer conducted by multi-disciplinary team[J]. Chin J Nurs, 2016,51(5):542-546.
[2]	Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer[J]. N Engl J Med, 2018,379(25):2395-2406. DOI URL PMID
[3]	Zhang LL, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer[J]. World J Gastroenterol, 2018,24(19):2047-2060. DOI URL PMID
[4]	Weldring T, Smith SM. Patient-reported outcomes(PROs) and patient-reported outcome measures(PROMs)[J]. Health Serv In-sights, 2013,6:61-68.
[5]	杨苏, 黄丽华. 患者自我报告结局在慢性阻塞性肺疾病患者中的应用进展[J]. 中华护理杂志, 2020,55(5):716-720.
	Yang S, Huang LH. Progress on the application of self-reported outcome measures in patients with chronic obstructive pulmonary disease[J]. Chin J Nurs, 2020,55(5):716-720.
[6]	皋文君, 袁长蓉. 患者自我报告结局测量信息系统在国外的应用进展[J]. 中华护理杂志, 2018,53(11):1401-1405.
	Gao WJ, Yuan CR. Application status of patient reported outcomes measurement information system in foreign countries[J]. Chin J Nurs, 2018,53(11):1401-1405.
[7]	吴冰, 张柳柳, 邾萍, 等. 乳腺癌患者对化疗不良反应的自我报告与护理记录的一致性研究[J]. 中华护理杂志, 2019,54(2):165-169.
	Wu B, Zhang LL, Zhu P, et al. Consistency study of self-reports and nursing notes in adjuvant chemotherapy-related side effects among patients with breast cancer[J]. Chin J Nurs, 2019,54(2):165-169.
[8]	Kyte DG, Calvert M, van der Wees PJ, et al. An introduction to patient-reported outcome measures(PROMs) in physiotherapy[J]. Physiotherapy, 2015,101(2):119-125. DOI URL PMID
[9]	U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research,U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research,U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry:patient-reported outcome measures:use in medical product development to support labeling claims:draft guidance[J]. Health Qual Life Outcomes, 2006,4:79. DOI URL PMID
[10]	Fiscella K, Ransom S, Jean-Pierre P, et al. Patient-reported out-come measures suitable to assessment of patient navigation[J]. Cancer, 2011,117(15 Suppl):3603-3617. DOI URL PMID
[11]	Frosch DL. Patient-reported outcomes as a measure of healthcare quality[J]. J Gen Intern Med, 2015,30(10):1383-1384. DOI URL PMID
[12]	Bartlett SJ, Ahmed S. Montreal accord on Patient-reported out-comes(PROs) use series-paper 1:introduction[J]. J Clin Epidemiol, 2017,89:114-118. DOI URL PMID
[13]	Kluetz PG, Chingos DT, Basch EM, et al. Patient-reported outcomes in cancer clinical trials:measuring symptomatic adverse events with the national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events(PRO-CTCAE)[J]. Am Soc Clin Oncol Educ Book, 2016,35:67-73. DOI URL PMID
[14]	隆莉芝, 袁玲. 患者报告结局的应用近况及思考[J]. 中国全科医学, 2020,23(32):4120-4127.
	Long LZ, Yuan L. The application and consideration of patient-reported outcomes[J]. Chin Gene Prac, 2020,23(32):4120-4127.
[15]	Schifferdecker KE, Yount SE, Kaiser K, et al. A method to create a standardized generic and condition-specific patient-reported outcome measure for patient care and healthcare improvement[J]. Qual Life Res, 2018,27(2):367-378. DOI URL PMID
[16]	Ahmad FS, Kallen MA, Schifferdecker KE, et al. Development and initial validation of the PROMIS-plus-HF profile measure[J]. Circ Heart Fail, 2019,12(6):e005751. DOI URL PMID
[17]	Fogelman DR, Morris J, Xiao L, et al. A predictive model of inflammatory markers and patient-reported symptoms for Cachexia in newly diagnosed pancreatic cancer patients[J]. Support Care Cancer, 2017,25(6):1809-1817. DOI URL PMID
[18]	Hammad A, Davis LE, Mahar AL, et al. Symptom trajectories and predictors of severe symptoms in pancreatic adenocarcinoma at the end-of-life:a population based analysis of 2 538 patients[J]. HPB(Oxford), 2019,21(12):1744-1752.
[19]	Dobratz MC. Word choices of advanced cancer patients:frequency of nociceptive and neuropathic pain[J]. Am J Hosp Palliat Care, 2008,25(6):469-475. DOI URL PMID
[20]	Seicean A, Cainap C, Gulei I, et al. Pain palliation by endoscopic ultrasound-guided celiac plexus neurolysis in patients with unresectable pancreatic cancer[J]. J Gastrointestin Liver Dis, 2013,22(1):59-64. URL PMID
[21]	李理, 李书平, 姜红. 某中心医院胰腺癌患者抑郁伴发特征及其与生存质量的相关性分析[J]. 解放军预防医学杂志, 2018,36(2):267-270.
	Li L, Li SP, Jiang H. Depression associated with pancreatic cancer in a downtown hospital and correlations with quality of life[J]. J Prev Med Chin PLA, 2018,36(2):267-270.
[22]	Romanus D, Kindler HL, Archer L, et al. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B(CALGB 80303)[J]. J Pain Symptom Manag, 2012,43(2):205-217. DOI URL
[23]	Bernhard J, Dietrich D, Glimelius B, et al. Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy[J]. Br J Cancer, 2010,103(9):1318-1324. DOI URL PMID
[24]	Moningi S, Walker AJ, Hsu CC, et al. Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic[J]. J Oncol Pract, 2015,11(2):e216-e221. DOI URL PMID
[25]	Tang CC, Von Ah D, Fulton JS. The symptom experience of patients with advanced pancreatic cancer:an integrative review[J]. Cancer Nurs, 2018,41(1):33-44. DOI URL PMID
[26]	Hankins MC, Llewellyn CD. Is the Satisfaction with Cancer Information Profile(SCIP) valid for tailoring information for patients with head and neck cancer[J]. BMC Cancer, 2008,8(1):164. DOI URL
[27]	Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30:a quality-of-life instrument for use in international clinical trials in oncology[J]. J Natl Cancer Inst, 1993,85(5):365-376. DOI URL PMID
[28]	Fitzsimmons D, Johnson CD, George S, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire,the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life[J]. Eur J Cancer, 1999,35(6):939-941. DOI URL PMID
[29]	万崇华, 陈明清, 张灿珍, 等. 癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J]. 实用肿瘤杂志, 2005,20(4):353-355.
	Wan CH, Chen MQ, Zhang CZ, et al. Evaluation of the Chinese version of the EORTC QLQ-C30 scale for Cancer Patients[J]. J Prac Oncol, 2005,20(4):353-355.
[30]	周燕梅. 癌症患者生命质量测定量表体系之胰腺癌量表QLICP-PA的研制与评价[D]. 昆明:昆明医科大学, 2018.
	Zhou YM. Development and Evaluation of Quality of Life Instrument for Patients with Pancreatic Cancer(QLICP-PA)[D]. Kunming:Kunming Medical University, 2018.
[31]	Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale:development and validation of the general measure[J]. J Clin Oncol, 1993,11(3):570-579. DOI URL PMID
[32]	Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy(FACT) qua-lity of life measurement system[J]. Qual Life Res, 1996,5(3):309-320. DOI URL PMID
[33]	van Buren G 2nd, Bloomston M, Schmidt CR, et al. A pros-pective randomized multicenter trial of distal pancreatectomy with and without routine intraperitoneal drainage[J]. Ann Surg, 2017,266(3):421-431. DOI URL PMID
[34]	Lipton A, Campbell-Baird C, Witters L, et al. Phase II trial of gemcitabine,irinotecan,and celecoxib in patients with adva-nced pancreatic cancer[J]. J Clin Gastroenterol, 2010,44(4):286-288. DOI URL PMID
[35]	Heffernan N, Cella D, Webster K, et al. Measuring health-related quality of life in patients with hepatobiliary cancers:the functional assessment of cancer therapy-hepatobiliary questionnaire[J]. J Clin Oncol, 2002,20(9):2229-2239. DOI URL PMID
[36]	Cella D, Butt Z, Kindler HL, et al. Validity of the FACT Hepa-tobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer[J]. Qual Life Res, 2013,22(5):1105-1112. DOI URL
[37]	Crippa S, Domínguez I, Rodríguez JR, et al. Quality of life in pancreatic cancer:analysis by stage and treatment[J]. J Gastrointest Surg, 2008,12(5):783-794. DOI URL
[38]	朱兆承, 郎庆波, 陈喆, 等. 肝胆肿瘤治疗功能评定量表中文版的考评[J]. 中西医结合学报, 2008,6(4):341-345.
	Zhu ZC, Lang QB, Chen Z. et al. Evaluation of Chinese version of the Functional Assessment of Cancer Therapy-Hepatobiliary questionnaire[J]. J Chin Integr Med, 2008,6(4):341-345.
[39]	马瑞珩, 叶志霞, 赵洁, 等. 恶性梗阻性黄疸患者生命质量特异性条目池的研制[J]. 解放军护理杂志, 2009,26(21):32-33,51.
	Ma RH, Ye ZX, Zhao J. et al. Development of a pool of specific items of quality of life for patients with malignant obstructive jaundice[J]. Nurs J Chin PLA, 2009,26(21):32-33,51.